Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,140 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Flu Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)

NCT00380237
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 21, 2008 · Synced Oct 24, 2026, 6:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Galactooligosaccharide, Immune Strength, and Digestive Health

NCT01137760
View directory record Official record
Conditions
Healthy
Interventions
Sucrose, Galactooligosaccharide
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
427 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 24, 2026, 6:48 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Screening for LID Clinical Studies Unit Healthy Volunteer Protocols

NCT01386424
View directory record Official record
Conditions
Zika, Influenza
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 24, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

NCT01231620
View directory record Official record
Conditions
Influenza, Human
Interventions
Zanamivir, Placebo to match zanamivir, Oseltamivir, Placebo to match oseltamivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 24, 2026, 6:48 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks

NCT05012189
View directory record Official record
Conditions
Influenza, Influenza, Human, Influenza -Like Illness
Interventions
Oseltamivir, Baloxavir
Drug
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
18 Years to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 24, 2026, 6:48 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Flu COVID Vaccine Views

NCT07871448
View directory record Official record
Conditions
Influenza, COVID-19, Vaccination Willingness
Interventions
Survey
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 89 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 24, 2026, 6:48 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

NCT05874713
View directory record Official record
Conditions
Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions
aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on Day 22, aH5N6c on Day 22, aH5N8c on Day 202
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
9
States / cities
Cullman, Alabama • Lilburn, Georgia • Norcross, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 24, 2026, 6:48 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

NCT05827926
View directory record Official record
Conditions
SARS-CoV-2, Influenza
Interventions
Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2, mRNA-1083.3, Investigational Influenza Vaccine 1, Investigational COVID-19 Vaccine 1, COVID-19 Vaccine 1, Investigational Influenza Vaccine 2, Influenza Vaccine 2, mRNA-1083, Investigational COVID-19 Vaccine 2, COVID-19 Vaccine 2
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
1,758 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
69
States / cities
Chandler, Arizona • Colton, California • Huntington Beach, California + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 24, 2026, 6:48 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age

NCT00966238
View directory record Official record
Conditions
Influenza
Interventions
VAX125
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
Lanexa, Kansas • Rochester, New York • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 24, 2026, 6:48 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Opioid, HIV and Immune System

NCT04304768
View directory record Official record
Conditions
Immune Defect
Interventions
Fluzone Quadrivalent
Biological
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 24, 2026, 6:48 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparison of Inactivated and Live, Attenuated Influenza Vaccine in Children 5-9 Years of Age-Year 3 Amendment

NCT00138385
View directory record Official record
Conditions
Influenza
Interventions
FluMist, Fluzone
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 9 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 24, 2026, 6:48 AM EDT
Completed Not applicable Interventional Results available

PregText: Feasibility of Monitoring Influenza Vaccine Safety in Pregnant Women Using Text Messaging

NCT01974050
View directory record Official record
Conditions
Pregnancy
Interventions
Text message surveillance
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 24, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

NCT03895385
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 24, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

NCT03300050
View directory record Official record
Conditions
Influenza, Vaccine
Interventions
cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS)
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 39 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 24, 2026, 6:48 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

H5N1 Milk Detection Study

NCT06850298
View directory record Official record
Conditions
Influenza
Interventions
Pasteurized milk contaminated with killed A(H5) virus
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 24, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05

NCT02255409
View directory record Official record
Conditions
Influenza
Interventions
Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), non-adjuvanted Quadrivalent Influenza Vaccine (QIV)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
12 Months to 84 Months
Enrollment
607 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
19
States / cities
San Diego, California • San Gabriel, California • Colorado Springs, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 24, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001

NCT01403155
View directory record Official record
Conditions
Healthy
Interventions
INO-3401 + EP
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Overland Park, Kansas • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 24, 2026, 6:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Transfer Factor to Prevent Upper Respiratory Tract Infections in Healthy Adults

NCT01106183
View directory record Official record
Conditions
Upper Respiratory Tract Infections Due to Influenza or Rhinovirus
Interventions
transfer factor, Placebo
Dietary Supplement
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 40 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 24, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

NCT05044195
View directory record Official record
Conditions
Influenza, Human
Interventions
aQIV, Comparator QIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
50 Years to 64 Years
Enrollment
2,044 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Mobile, Alabama • Tempe, Arizona • Atlantis, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 24, 2026, 6:48 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59

NCT06560151
View directory record Official record
Conditions
Influenza
Interventions
3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A, 3.75 µg H5N1 antigen plus MF59, 7.5 µg H5N1 antigen plus MF59, 15 µg H5N1 antigen plus MF59
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years and older
Enrollment
1,380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
20
States / cities
Atlanta, Georgia • Savannah, Georgia • Oak Lawn, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 24, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)

NCT00566345
View directory record Official record
Conditions
Influenza
Interventions
Inactivated seasonal influenza vaccine (split virus, Vero cell-derived), Phosphate buffered saline
Biological · Other
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
3,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
34
States / cities
Tucson, Arizona • Anaheim, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 24, 2026, 6:48 AM EDT
Completed No phase listed Observational

Influenza Vaccine in Premature Infants

NCT00455169
View directory record Official record
Conditions
Influenza, Infant, Premature
Interventions
Trivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
University of Rochester
Other
Eligibility
6 Months to 17 Months
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Miami, Florida • Buffalo, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2015 · Synced Oct 24, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over

NCT00232947
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (Fluviral), Influenza virus vaccine (Fluzone)
Biological
Lead sponsor
ID Biomedical Corporation, Quebec
Industry
Eligibility
50 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
10
States / cities
Pembroke Pines, Florida • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2007 · Synced Oct 24, 2026, 6:48 AM EDT
Completed Phase 2 Interventional Results available

A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza

NCT00705406
View directory record Official record
Conditions
Acute, Uncomplicated Human Influenza
Interventions
Peramivir, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 24, 2026, 6:48 AM EDT